Medartis builds on momentum with 16% organic sales growth and core EBITDA margin exceeding 18%

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

Release of an ad hoc announcement pursuant to Art. 53 LR. The issuer is solely responsible for the content of this announcement.

• Core sales^[1] in 2025 grew organically 15.7% (CER) to CHF 266.1 million (total sales: CHF 269.3 million), driven by double-digit growth in all regions and segments
• Overall cost discipline drives core EBITDA margin to 18.4% (reported: 19.1%) despite significant currency and additional customs burdens
• Keri Medical and NeoOrtho businesses were consolidated in May and July and achieved accretive sales growth in 2025 of 30% and 17%, respectively
• M&A: Medartis signs definitive agreement to acquire Belgian CADskills, expanding its patient-specific offering for head and hand surgery
• Guidance 2026: Medartis expects organic core sales growth of 16% – 18% and a core EBITDA margin in the high teens (at CER)